Advertisement
U.S. markets open in 4 hours 10 minutes
  • S&P Futures

    5,306.00
    -2.25 (-0.04%)
     
  • Dow Futures

    40,152.00
    +8.00 (+0.02%)
     
  • Nasdaq Futures

    18,489.25
    -14.50 (-0.08%)
     
  • Russell 2000 Futures

    2,135.20
    -3.20 (-0.15%)
     
  • Crude Oil

    81.61
    +0.26 (+0.32%)
     
  • Gold

    2,213.20
    +0.50 (+0.02%)
     
  • Silver

    24.51
    -0.24 (-0.98%)
     
  • EUR/USD

    1.0781
    -0.0049 (-0.45%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    12.96
    +0.18 (+1.41%)
     
  • GBP/USD

    1.2588
    -0.0050 (-0.39%)
     
  • USD/JPY

    151.4770
    +0.2310 (+0.15%)
     
  • Bitcoin USD

    70,693.01
    +960.39 (+1.38%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,954.19
    +22.21 (+0.28%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FENC, ODT and NKLA

NEW YORK, NY / ACCESSWIRE / October 15, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
Class Period: February 11, 2020 - August 10, 2020
Lead Plaintiff Deadline: November 2, 2020

The complaint alleges that during the class period Fennec Pharmaceuticals Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the manufacturing facilities for PEDMARK, the Company's sole product candidate, did not comply with current good manufacturing practices; (2) as a result, regulatory approval for PEDMARK was reasonably likely to be delayed; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in FENC: http://www.kleinstocklaw.com/pslra-1/fennec-pharmaceuticals-inc-loss-submission-form?id=10182&from=1

Odonate Therapeutics, Inc. (NASDAQ:ODT)
Class Period: December 7, 2017 - April 21, 2020
Lead Plaintiff Deadline: November 16, 2020

The ODT lawsuit alleges Odonate Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (i) the Company's orally administered chemotherapy agent, tesetaxel, was not as safe or well-tolerated as the Company had led investors to believe; (ii) consequently, tesetaxel's commercial viability as a cancer treatment was overstated; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in ODT: http://www.kleinstocklaw.com/pslra-1/odonate-therapeutics-inc-loss-submission-form?id=10182&from=1

Nikola Corporation, f/k/a VectoIQ Acquisition Corp. (NASDAQ:NKLA)
Class Period: March 3, 2020 - September 15, 2020
Lead Plaintiff Deadline: November 16, 2020

Nikola Corporation, f/k/a VectoIQ Acquisition Corp. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) VectoIQ did not engage in proper due diligence regarding its merger with Nikola; (2) Nikola overstated its “in-house” design, manufacturing, and testing capabilities; (3) Nikola overstated its hydrogen production capabilities; (4) as a result, Nikola overstated its ability to lower the cost of hydrogen fuel; (5) Nikola founder and Executive Chairman, Trevor Milton, tweeted a misleading “test” video of the Company's Nikola Two truck; (6) the work experience and background of key Nikola employees, including Mr. Milton, had been overstated and obfuscated; (7) Nikola did not have five Tre trucks completed; and (8) as a result, defendants' public statements were materially false and/or misleading at all relevant times.

Learn about your recoverable losses in NKLA: http://www.kleinstocklaw.com/pslra-1/nikola-corporation-f-k-a-vectoiq-acquisition-corp-loss-submission-form?id=10182&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/610733/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-FENC-ODT-and-NKLA

Advertisement